Loading clinical trials...
Loading clinical trials...
A Phase 2/3, Multicenter, Randomized, Double-blinded, Placebo-controlled, Repeat-dose Study to Evaluate the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency
Conditions
Interventions
placebo (saline)
Olipudase alfa
Locations
24
United States
UCSF Medical Center Site Number : 840005
San Francisco, California, United States
Emory University Site Number : 840003
Decatur, Georgia, United States
Montefiore Medical Center Site Number : 840006
The Bronx, New York, United States
Investigational Site Number : 032001
Córdoba, Argentina
Investigational Site Number : 036001
Westmead, New South Wales, Australia
Investigational Site Number : 056001
Leuven, Belgium
Start Date
December 18, 2015
Primary Completion Date
March 15, 2021
Completion Date
October 19, 2023
Last Updated
November 7, 2024
Lead Sponsor
Genzyme, a Sanofi Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions